Shares of small-cap pharmaceutical player Sudarshan Pharma Industries attracted significant market attention during the trading session following a major overseas expansion announcement. The company disclosed plans to acquire a minority stake in an American biotechnology firm to broaden its international footprint.
Acquisition Details and Timeline
Sudarshan Pharma Industries Ltd intends to purchase nearly 24.24 lakh equity shares, representing 9.50 percent of the total issued and outstanding share capital of US-based MedTherapy Biotechnology Inc. The transaction involves a cash investment denominated in US dollars.
The board of directors approved the proposed transaction, which was formally communicated through an exchange filing on September 5. The final purchase consideration will be determined based on the valuation applicable to MedTherapy at the time of completion. Sudarshan Pharma targets March 31, 2027, to finalize the acquisition, pending regulatory approvals and other standard conditions.
Promoter Investments and Regulatory Compliance
Alongside the corporate investment, Chairman and Managing Director Hemal Mehta and Joint Managing Director Sachin Mehta are planning individual investments in the biotech firm. Both promoters aim to secure a 1.50 percent stake each in MedTherapy.
The cross-border investment will proceed under the provisions of the Foreign Exchange Management Act and India's overseas investment framework. According to the company, the transaction qualifies under the Reserve Bank of India's automatic route provided all requisite conditions are satisfied.
Operational Focus of MedTherapy
MedTherapy Biotechnology operates out of Boston, specializing in advanced cancer cell and gene therapies, including CAR-T cell therapy, which utilizes specially engineered immune cells to combat cancer.
The firm functions as an integrated contract development and manufacturing organization for these therapies. It maintains a commercial-scale GMP manufacturing facility in New Delhi alongside a technology development centre in Boston.
Market Performance and Stock Movement
On September 7, 2026, Sudarshan Pharma shares traded at Rs 40.85, registering an increase of 3.63 percent, or Rs 1.43, during the session. The stock opened at Rs 40.25, touched an intraday high of Rs 41.39, and recorded a low of Rs 40.25. On the preceding Friday, the stock closed nearly 1 percent higher at Rs 39.42. The company holds a market capitalisation of approximately Rs 984 crore as of September 4.
The stock has delivered strong returns over multiple timeframes, rising more than 15 percent over the past month and over 52 percent across the last six months. Over a three-year horizon, the small-cap pharmaceutical counter has posted substantial gains for long-term investors, keeping market participants focused on its ongoing developments.
